Citations

Clear

2416 citation(s) found for "Yu, Jason".

Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort
Leister, Erin, Coryell, Jason , Nickels, Katherine , Ryan, Nicole, Juarez‐Colunga, Elizabeth , Gaillard, William D. , Mytinger, John R. , Berg, Anne T. , Millichap, J Gordon , Nordli, Douglas R. , Joshi, Sucheta M. , Shellhaas, Renée A. , Loddenkemper, Tobias , Dlugos, Dennis , Sullivan, Joseph , Hartman, Adam L. , Kossoff, Eric H. , Grinspan, Zachary M. , Hamikawa, Lorie, Wusthoff, Courtney J. , Novotny, Edward J. , Yozawitz, Elissa , Millichap, John , Knupp, Kelly G. , Wirrell, Elaine , Shellhaas, Renée A , Novotny, Edward J , Gaillard, William D , Loddenkemper, Tobias , Yozawitz, Elissa G , Berg, Anne T , Grinspan, Zachary , Nickels, Katherine C , Coryell, Jason , Wusthoff, Courtney J

Mayo Clinic

Epilepsia | September 12, 2016 | Volume: 57 | Issue: 11 | Pages: 1834-1842

10.1111/epi.13557 | PMID 27615012 Get It

Summary Objective Infantile spasms ( IS ) represent a severe epileptic encephalopathy presenting in the first 2 years of life. Recommended first‐line therapies (hormonal therapy or vigabatrin) often fail. We evaluated response to second treatment for IS in children in whom the initial therapy failed to produce both clinical remission and electrographic resolution of hypsarhythmia and whether time to treatment was related to outcome. Methods The National Infantile Spasms Consortium established a multicenter, prospective database enrolling infants with new diagnosis of IS. Children were considered nonresponders to first treatment if there was no clinical remission or persistence of hypsarhythmia. Treatment was evaluated as hormonal therapy (adrenocorticotropic hormone [ ACTH ] or oral corticosteroids), vigabatrin, or “other.” Standard treatments (hormonal and vigabatrin) were compared to all other nonstandard treatments. We compared response rates using chi‐square tests and multivariable logistic regression models. Results One hundred eighteen infants were included from 19 centers. Overall response rate to a second treatment was 37% (n = 44). Children who received standard medications with differing mechanisms for first and second treatment had higher response rates than other sequences (27/49 [55%] vs. 17/69 [25%], p < 0.001). Children receiving first treatment within 4 weeks of IS onset had a higher response rate to second treatment than those initially treated later (36/82 [44%] vs. 8/34 [24%], p = 0.040). Significance Greater than one third of children with IS will respond to a second medication. Choosing a standard medication ( ACTH , oral corticosteroids, or vigabatrin) that has a different mechanism of action appears to be more effective. Rapid initial treatment increases the likelihood of response to the second treatment.
Detectors for in vivo range and dose verification in proton therapy
Blyth, D. , Galyaev, E., Holmes, Jason , Ice, Lauren , Randall, Glenn , Fatyga, M., Alarcón, Ricardo , Bues, Martin , Holmes, Jason M

Mayo Clinic

International Journal of Modern Physics: Conference Series | September 1, 2016 | Volume: 44 | Issue: No issue available | Pages: 1660217

10.1142/s2010194516602179 Get It

Particle detection instrumentation to address the in vivo verifications of proton dose and range is under development as part of a proton therapy research program focused on patient quality assurance. For in vivo proton range verification, a collimated gamma detector array is under construction to indirectly measure the position of the Bragg peak for each proton beam spot to within 1–2 mm precision. For dose flux verification, a proton fluence detector based on the technology of the Micromegas is under construction. This detector has an active area of about 100 cm2, coordinate resolution of better than 1 mm, and handling of incident proton beam fluxes of 109–1013 particles/s.
Low incidence of pneumocystis pneumonia utilizing PCR‐based diagnosis in patients with B‐cell lymphoma receiving rituximab‐containing combination chemotherapy
Barreto, Jason N. , Ice, Lauren L., Thompson, Carrie A. , Tosh, Pritish K. , Osmon, Douglas R. , Dierkhising, Ross , Plevak, Matthew F., Dierkhising, Ross A, Limper, Andrew H.

Mayo Clinic

American Journal of Hematology | August 22, 2016 | Volume: 91 | Issue: 11 | Pages: 1113-1117

10.1002/ajh.24499 | PMID 27472910 Get It

Recent literature has demonstrated concern over the risk of Pneumocystis jirovecii pneumonia (PJP) when administering rituximab with combination chemotherapy such as in R‐CHOP; however, the exact risk and potential need for prophylaxis is unknown. We sought to determine the incidence of PJP infection following R‐CHOP administration in patients with B‐cell lymphoma. Consecutive patients diagnosed with B‐cell lymphoma receiving R‐CHOP were evaluated from chemotherapy initiation until 180 days after the last administration. The primary outcome was cumulative incidence of PJP infection. Secondary endpoints included the association of rituximab, prednisone and subsequent chemotherapy with PJP infection risk. A total of 689 patients (53% male, median age 66 years) were included. Seventy‐three percent of patients completed at least 6 cycles of R‐CHOP treatment. Median rituximab and prednisone cumulative doses were 3950 mg and 5325 mg, respectively. Median daily prednisone dose through end of treatment was 45 mg (range 7.6 mg to 119 mg). The cumulative incidence of PJP was 1.51% (95% CI 0.57–2.43, at maximum follow‐up of 330 days), below 3.5%, the conventional threshold for prophylaxis. Univariate analysis did not detect a statistically significant association between PJP and rituximab, steroids, or receipt of additional chemotherapy in this patient population. Our results demonstrate a low occurrence of Pneumocystis pneumonia during R‐CHOP treatment of B‐cell lymphoma and argue against universal anti‐Pneumocystis prophylaxis in this setting. Further investigations should focus on targeted anti‐Pneumocystis prophylaxis for patients presenting with high‐risk baseline characteristics or when receiving rituximab‐inclusive intensive combination chemotherapy regimens as treatment for other aggressive lymphoma subtypes. Am. J. Hematol. 91:1113–1117, 2016. © 2016 Wiley Periodicals, Inc.
Statistical Methods for Testing Genetic Pleiotropy
Schaid, Daniel J. , Tong, Xingwei, Larrabee, Beth R. , Kennedy, Richard B. , Sinnwell, Jason P. , Larrabee, Beth, Poland, Gregory A. , Sinnwell, Jason P , Kennedy, Richard

Mayo Clinic

Genetics | August 16, 2016 | Volume: 204 | Issue: 2 | Pages: 483-497

10.1534/genetics.116.189308 | PMID 27527515 Get It

AbstractGenetic pleiotropy is when a single gene influences more than one trait. Detecting pleiotropy and understanding its causes can improve the biological understanding of a gene in multiple ways, yet current multivariate methods to evaluate pleiotropy test the null hypothesis that none of the traits are associated with a variant; departures from the null could be driven by just one associated trait. A formal test of pleiotropy should assume a null hypothesis that one or no traits are associated with a genetic variant. For the special case of two traits, one can construct this null hypothesis based on the intersection-union (IU) test, which rejects the null hypothesis only if the null hypotheses of no association for both traits are rejected. To allow for more than two traits, we developed a new likelihood-ratio test for pleiotropy. We then extended the testing framework to a sequential approach to test the null hypothesis that k+1 traits are associated, given that the null of k traits are associated was rejected. This provides a formal testing framework to determine the number of traits associated with a genetic variant, while accounting for correlations among the traits. By simulations, we illustrate the type I error rate and power of our new methods; describe how they are influenced by sample size, the number of traits, and the trait correlations; and apply the new methods to multivariate immune phenotypes in response to smallpox vaccination. Our new approach provides a quantitative assessment of pleiotropy, enhancing current analytic practice.
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy
Tendulkar, Rahul D. , Agrawal, Shree , Gao, Tianming , Pisansky, Thomas M. , Michalski, Jeff M. , Hamstra, Daniel A. , Feng, Felix Y. , Liauw, Stanley L. , Abramowitz, Matthew C. , Pollack, Alan , Den, Robert B. , Stephans, Kevin L. , Zietman, Anthony L., Lee, W. Robert , Kattan, Michael W. , Stephenson, Andrew J. , Efstathiou, Jason A. , Koontz, Bridget F, Anscher, Mitchell S. , Moghanaki, Drew, Koontz, Bridget F. , Moghanaki, Drew M. , Den, Robert B , Liauw, Stanley L , Abramowitz, Matthew C , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | August 15, 2016 | Volume: 34 | Issue: 30 | Pages: 3648-3654

10.1200/jco.2016.67.9647 | PMID 27528718 Get It

Purpose We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era. Methods Individual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated. Results Overall, 2,460 patients with a median follow-up of 5 years were included; 599 patients (24%) had a Gleason score (GS) ≤ 6, 1,387 (56%) had a GS of 7, 244 (10%) had a GS of 8, and 230 (9%) had a GS of 9 to 10. There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positive surgical margins, and 390 (16%) who received ADT (median, 6 months). The median pre-SRT PSA was 0.5 ng/mL (interquartile range, 0.3 to 1.1). The 5-yr FFBF rate was 56% overall, 71% for those with a pre-SRT PSA level of 0.01 to 0.2 ng/mL (n = 441), 63% for those with a PSA of 0.21 to 0.50 ng/mL (n = 822), 54% for those with a PSA of 0.51 to 1.0 ng/mL (n = 533), 43% for those with a PSA of 1.01 to 2.0 ng/mL (n = 341), and 37% for those with a PSA > 2.0 ng/mL (n = 323); P < .001. On multivariable analysis, pre-SRT PSA, GS, EPE, SVI, surgical margins, ADT use, and SRT dose were associated with FFBF. Pre-SRT PSA, GS, SVI, surgical margins, and ADT use were associated with DM, whereas EPE and SRT dose were not. The nomogram concordance indices were 0.68 (FFBF) and 0.74 (DM). Conclusion Early SRT at low PSA levels after RP is associated with improved FFBF and DM rates. Contemporary nomograms can estimate individual patient outcomes after SRT in the modern era.
Treatment of Refractory Postdural Puncture Headache after Intrathecal Drug Delivery System Implantation with Epidural Blood Patch Procedures: A 20-Year Experience
Bendel, Markus A. , Moeschler, Susan M. , Qu, Wenchun , Hanley, Eugerie, Neuman, Stephanie, Eldrige, Jason S. , Hoelzer, Bryan C. , Neuman, Stephanie A

Mayo Clinic

Pain Research and Treatment | August 11, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-5

10.1155/2016/2134959 | PMID 27597897 Get It

A recent publication reported the incidence of postdural puncture headache (PDPH) in conjunction with intrathecal drug delivery system (IDDS) implantation to be nearly 23 percent. Many patients responded to conservative measures but a percentage needed invasive treatment with an epidural blood patch (EBP). There is limited data to describe the technical details, success rates, and complications associated with EBP in this population. This study aims to provide a retrospective report of EBP for patients suffering from PDPH related to IDDS implantation. A chart review established a cohort of patients that required EBP in relation to a PDPH after IDDS implantation. This cohort was evaluated for demographic data as well as details of the EBP including technical procedural data, success rates, and complications. All patients received a trial of conservative therapy. Standard sterile technique and skin preparation were utilized with no infectious complications. The EBP was placed below the level of the IDDS catheter in 94% of procedures. Fluoroscopy was utilized in each case. The mean EBP volume was 18.6 cc and median time of EBP was day 7 after implant. There were no complications associated with EBP. EBP appears to be an effective intervention in this subset of PDPH patients.
Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant
Cheng, Guang‐Shing , Storer, Barry E. , Chien, Jason W. , Jagasia, Madan , Hubbard, Jesse J., Burns, Linda J. , Ho, Vincent T. , Pidala, Joseph, Palmer, Jeanne , Johnston, Laura , Mayer, Sebastian , Crothers, Kristina , Pusic, Iskra , Lee, Stephanie J. , Williams, Kirsten M. , Crothers, Kristina , Lee, Stephanie J

Mayo Clinic

Annals of the American Thoracic Society | August 11, 2016 | Volume: 13 | Issue: 11 | Pages: 1932-1939

10.1513/annalsats.201604-262oc | PMID 27513368 Get It

Abstract Rationale The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary for prompt clinical recognition and treatment and also for the rational design of prospective studies. Objectives To describe the longitudinal trajectory of lung function parameters, including FEV1, in patients with BOS after hematopoietic cell transplant. Methods Subjects with BOS defined by National Institutes of Health consensus guidelines criteria from a recent multicenter prospective trial of combination treatment with fluticasone, azithromycin and montelukast and a retrospective cohort from Fred Hutchinson Cancer Research Center were included. Longitudinal change in FEV1 for each patient was calculated on the basis of available pulmonary function tests in three periods: pre-BOS, from BOS diagnosis to 6 months, and 6–18 months after diagnosis. The effect of treatment on FEV1 trajectory was analyzed by univariate and multivariate linear regression. The Kaplan-Meier method was used to estimate survival. Measurements and Main Results: The FEV1 percent predicted value at diagnosis was 46% (interquartile range, 35–57%) for trial participants and 53% (interquartile range, 41–64%) for the retrospective cohort. There was a concomitant mild reduction in FVC, as well as a marked reduction in forced expiratory flow, midexpiratory phase, at diagnosis. While there was individual heterogeneity, the overall FEV1 trajectory was characterized by a marked decline within 6 months prior to BOS diagnosis, followed by stability of FEV1 early after diagnosis and a slow rate of decline beyond 6 months. The effect of the trial medications on FEV1 trajectory after BOS diagnosis was a mean rate of change of 0.92% predicted per month (95% confidence interval, −0.53 to 2.37) compared with the retrospective cohort, but this was not statistically significant. Two-year overall survival rates were 76% and 72% for the study participants and the retrospective cohort patients, respectively. Earlier time to diagnosis after hematopoietic cell transplant and severity of FVC at diagnosis were significantly associated with reduced survival. Conclusions The FEV1 trajectory in patients with BOS after hematopoietic cell transplant in a contemporary era of management follows a predominant pattern of rapid FEV1 decline in the 6 months prior to diagnosis, followed by FEV1 stabilization after diagnosis.
Characterization of C3 in C3 glomerulopathy
Sethi, Sanjeev , Vrana, Julie A., Theis, Jason D. , Sethi, Amit , Kurtin, Paul J. , Smith, Richard J. , Fervenza, Fernando C. , Zhang, Yuzhou

Mayo Clinic

Nephrology Dialysis Transplantation | August 9, 2016 | Volume: 32 | Issue: 3 | Pages: 459-465

10.1093/ndt/gfw290 | PMID 27507892 Get It

Abstract Background: C3 glomerulopathy (C3G) is caused by overactivity of the alternative pathway of complement that results in bright glomerular C3 staining with minimal or no deposition of immunoglobulins on immunofluorescence microscopy. Laser microdissection and mass spectrometry of the two subtypes, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), have identified C3 as the predominant glomerular complement protein, although lesser amounts of C9, C5, C6, C7 and C8 are detectable. C3 plays a central role in complement activity, with its proteolytic cleavage first generating C3a and C3b, followed by inactivation of C3b generating iC3b (which includes C3α and C3β), which undergoes further breakdown yielding C3c and terminal breakdown fragment C3dg. The composition of C3 breakdown products in C3G is not known. Methods: In this study, we chose six cases each of C3GN and DDD to analyze the composition of C3 deposits. We analyzed the amino acid sequence of C3 spectra detected by mass spectrometry to determine the relative abundance of C3 fragments in C3G. Thus we were able to determine the amino acid sequences mapping to the various C3 activation products including C3dg, C3α (C3α1 and α2), and C3β that are part of C3b/iC3b/C3c. Results: C3dg is the predominant cleavage product detected with the highest amino acid coverage. The remaining amino acids map to C3α (C3α1 and α2) and C3β. Amino acids mapping to C3a and C3f are absent. Taken together, the C3α and C3β amino acids represent iC3b prior to or after C3c cleavage of C3dg. The C3 spectra for both C3GN and DDD are surprisingly similar. Conclusion: The finding of large amounts of C3dg suggests that C3b deposition in the glomerulus is an active process triggered by thioester binding of C3b to the glycocalyx overlying the glomerular endothelial cells and glomerular basement membrane. Regulatory protein-mediated inactivation of C3b results in the generation of iC3b. After additional cleavages, mostly C3dg remains.
Circadian variation of the pancreatic islet transcriptome
Rakshit, Kuntol, Qian, Jingyi , Ernst, Jason , Matveyenko, Aleksey V.

Mayo Clinic

Physiological Genomics | August 5, 2016 | Volume: 48 | Issue: 9 | Pages: 677-687

10.1152/physiolgenomics.00019.2016 | PMID 27495157 Get It

Pancreatic islet failure is a characteristic feature of impaired glucose control in diabetes mellitus. Circadian control of islet function is essential for maintaining proper glucose homeostasis. Circadian variations in transcriptional pathways have been described in diverse cell types and shown to be critical for optimization of cellular function in vivo. In the current study, we utilized Short Time Series Expression Miner (STEM) analysis to identify diurnally expressed transcripts and biological pathways from mouse islets isolated at 4 h intervals throughout the 24 h light-dark cycle. STEM analysis identified 19 distinct chronological model profiles, and genes belonging to each profile were subsequently annotated to significantly enriched Kyoto Encyclopedia of Genes and Genomes biological pathways. Several transcriptional pathways essential for proper islet function (e.g., insulin secretion, oxidative phosphorylation), cell survival (e.g., insulin signaling, apoptosis) and cell proliferation (DNA replication, homologous recombination) demonstrated significant time-dependent variations. Notably, KEGG pathway analysis revealed “protein processing in endoplasmic reticulum - mmu04141” as one of the most enriched time-dependent pathways in islets. This study provides unique data set on time-dependent diurnal profiles of islet gene expression and biological pathways, and suggests that diurnal variation of the islet transcriptome is an important feature of islet homeostasis, which should be taken into consideration for optimal experimental design and interpretation of future islet studies.
Multiplex matrix network analysis of protein complexes in the human TCR signalosome
Smith, Stephen , Neier, Steven C. , Reed, Brendan , Davis, Tessa R. , Sinnwell, Jason P. , Eckel‐Passow, Jeanette E. , Sciallis, Gabriel F., Wieland, Carilyn N. , Torgerson, Rochelle R. , Gil, Diana , Neuhauser, Claudia , Schrum, Adam G. , Smith, Stephen E P, Reed, Brendan K, Neuhauser, Claudia , Schrum, Adam G , Sinnwell, Jason P

Mayo Clinic

Science Signaling | August 2, 2016 | Volume: 9 | Issue: 439 | Pages: No page available

10.1126/scisignal.aad7279 | PMID 27485017 Get It

A multiplex antibody-mediated capture technique reveals patient-specific protein complexes.